Posted by Michael Wonder on 25 Apr 2026
Arrowhead Pharmaceuticals receives positive CHMP opinion recommending approval of Redemplo (plozasiran) to reduce triglycerides in adults with familial chylomicronaemia syndrome in Europe
24 April 2026 - The CHMP opinion is based on positive results from the Phase 3 PALISADE study where Redemplo reduced triglycerides by a median of 80% from baseline and significantly fewer cases of acute pancreatitis were seen in patients using Redemplo compared with those using placebo
Arrowhead Pharmaceuticals today announced that the EMA’s CHMP has adopted a positive opinion, recommending the approval of Redemplo (plozasiran), a small interfering RNA medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome.
